Video Experimental Relacionado
Updated: Jun 14, 2026
13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Capacidad del factor VIIa recombinante para generar trombina durante la inhibición del factor tisular en sujetos
P W Friederich1, M Levi, K A Bauer
1Department of Vascular Medicine and Internal Medicine, Academic Medical Center, University of Amsterdam, Netherlands.
Circulation
|May 31, 2001
Resumen
El factor VIIa recombinante (rVIIa) puede revertir los efectos anticoagulantes de la proteína c2 anticoagulante del nematodo, un inhibidor del factor tisular. Este hallazgo sugiere que rVIIa puede servir como un antídoto eficaz para las complicaciones hemorrágicas asociadas con los inhibidores de la vía del factor tisular.
Área de la Ciencia:
- La hemostasis y la trombosis
- Farmacología Farmacología.
- La bioquímica es la bioquímica.
Sus antecedentes:
- La vía del factor de tejido-factor VIIa es crucial para iniciar la coagulación sanguínea.
- Los nuevos anticoagulantes dirigidos a esta vía requieren estrategias de reversión efectivas para los eventos de sangrado.
- La proteína anticoagulante c2 del nematodo recombinante (rNAPc2) es un inhibidor específico del complejo factor-factor VIIa del tejido.
Objetivo del estudio:
- Investigar el potencial in vivo del factor VIIa recombinante (rVIIa) para inducir la generación de trombina.
- Evaluar la eficacia de rVIIa para revertir los efectos anticoagulantes de rNAPc2 en sujetos sanos.
Principales métodos:
- Diseño de estudio cruzado aleatorizado doble ciego.
- Administración de rNAPc2 seguido de rVIIa en voluntarios sanos.
- El monitoreo del tiempo de protrombina, el fragmento de activación de protrombina F1 + 2 y los complejos de trombina-antitrombina.
Principales resultados:
- La administración de rNAPc2 prolongó el tiempo de protrombina.
- La inyección posterior de rVIIa corrigió rápidamente el tiempo de protrombina e indujo una generación significativa de trombina.
- Se observaron niveles aumentados de F1 + 2 y complejos de trombina-antitrombina después de la administración de rVIIa.
- Los péptidos de activación del factor X y IX mostraron aumentos sustanciales.
Conclusiones:
- El factor VIIa recombinante induce efectivamente la generación de trombina incluso durante el tratamiento con un inhibidor del complejo factor-factor VIIa tisular.
- rVIIa demuestra potencial como un antídoto viable para revertir los efectos de los inhibidores de la vía del factor tisular.
- Este estudio pone de relieve una estrategia terapéutica prometedora para el manejo de las complicaciones hemorrágicas asociadas con las nuevas terapias anticoagulantes.
Videos de Conceptos Relacionados
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:09Coagulation
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.